



ASX ANNOUNCEMENT

26 August 2015

Tissue Therapies signs new commercial research agreement with QUT

Brisbane, 26 August 2015: Tissue Therapies (ASX: TIS), a biomedical technology company developing effective treatments for wound healing, announces today that it has signed a new R&D agreement with the Queensland University of Technology (QUT).

Tissue Therapies Acting CEO, Mr Nigel Johnson, said: "QUT has always been a highly professional and supportive R&D partner. On behalf of Tissue Therapies' Board and Management, I am very pleased to announce the continuation of our long-standing relationship through a new commercial research agreement."

"We appreciate QUT's significant contribution to Tissue Therapies' research and development efforts to date and look forward to utilising its expertise as we proceed."

In July 2015, Tissue Therapies secured absolute ownership of all intellectual property under five patent families relating to its lead candidate, VitroGro® ECM. The transfer of ownership served to provide the market with more certainty around the Company's assets and commercialisation potential.

VitroGro® ECM has been developed for use in the management of chronic wounds, in particular chronic venous leg ulcers, that do not follow the normal processes of wound repair and that have been present for more than four weeks despite conservative management.

Chronic wounds are characterised by a dysfunctional extracellular matrix (ECM) which blocks the movement of repair cells to the site. VitroGro® ECM is administered topically to the wound bed and acts as a replacement ECM, allowing repair cells to migrate, attach and proliferate, leading to tissue regenerate and, ultimately, wound closure.

- ENDS -

**For more information**

<p>Dr Cherrell Hirst, Interim Chairman Tissue Therapies Limited Cherrell@hirst.com</p> <p>Nigel Johnson, Acting CEO Tissue Therapies Limited Tel: +61 7 3334 3900 Email: n.johnson@tissuetherapies.com</p>	<p>Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au</p>
---	--

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company owns patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australia, Berlin and Frankfurt stock exchanges. For more information, please visit www.tissuetherapies.com.